Efficacy and safety of chiglitazar add‐on to metformin in type 2 diabetes mellitus ( RECAM study)

Documenti analoghi

• Efficacy and safety of tirzepatide in people with type 2 diabetes by baseline body mass index: An exploratory subgroup analysis of SURPASS‐AP‐Combo
  di: Jianhua Ma, et al.
  Pubblicazione: (2024)
• A 52‐week efficacy and safety study of enavogliflozin versus dapagliflozin as an add‐on to metformin in patients with type 2 diabetes mellitus: ENHANCE‐M extension study
  di: Tae Seo Sohn, et al.
  Pubblicazione: (2024)
• Efficacy and safety of dapagliflozin add‐on to evogliptin plus metformin therapy in patients with type 2 diabetes: A randomized, double‐blind, placebo‐controlled study
  di: In‐Kyung Jeong, et al.
  Pubblicazione: (2024)
• Cofrogliptin once every 2 weeks as add‐on therapy to metformin versus daily linagliptin in patients with type 2 diabetes in China: A randomized, double‐blind, non‐inferiority trial
  di: Qian Ren, et al.
  Pubblicazione: (2024)
• Efficacy and safety of cofrogliptin once every 2 weeks in Chinese patients with type 2 diabetes: A randomized, double‐blind, placebo‐controlled, phase 3 trial
  di: Leili Gao, et al.
  Pubblicazione: (2024)